Navigation Links
Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results
Date:11/14/2011

tilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications.  An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates.

Forward-Looking Statements Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to the Company's: (i) search for a new chief executive officer; (ii) expectations regarding the initial clinical trial of the Neo-Urinary Conduit and (iii) expectations regarding planned preclinical studies of the Neo-Kidney Augment. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there are a number of factors that may cause actual results to differ from these statements. For instance there can be no assurance that: (i) the Company will be able to find a suitable candidate for the position of chief executive officer or that the Company will be able to retain such person on mutually agreeable terms; (ii) the Company will be able to successfully enroll patients in its clinical trials, including its initial clinical trial for the Neo-Urinary Conduit; (iii)  the Company's Neo-Urinary Conduit clinical trial will not be
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Tengion Appoints Scott Flora to Board of Directors
2. Tengion Appoints Diane Jorkasky, M.D., to its Board of Directors
3. Tengion Provides Update on Neo-Urinary Conduit Clinical Trial
4. Tengion Announces FDA Orphan-Drug Designation for Neo-Urinary Conduit
5. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
6. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
7. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
10. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
11. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Express Scripts Holding Company (Nasdaq: ESRX ... Express Scripts stockholders of $515.2 million, or $0.67 per ... in Table 4, was $1.23 for the second quarter. ... serve our clients with scale, alignment and innovative solutions to ... outcomes of our members," stated George Paz, chairman and chief ...
(Date:7/29/2014)... , July 29, 2014 Pfenex Inc. (NYSE MKT: ... initial public offering of 8,333,333 shares of its common  stock ... All of the common stock was offered by Pfenex. In ... purchase up to 1,250,000 additional shares of common stock at ... are traded on the NYSE MKT under the symbol "PFNX." ...
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... environmental radiation measurement and monitoring, outsourced medical physics services ... results for the fiscal third quarter 2014 after the ... The Company will host a conference call for ... Central Time (10 a.m. Eastern Time). Investors may access ...
Breaking Medicine Technology:Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31Pfenex Announces Closing of Initial Public Offering 2Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2
... 21, 2012  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... conferences: , Citi 2012 Global Healthcare Conference at ... , RBC Capital Markets, Healthcare Conference at 9:00 ... The sessions may be accessed through the Company,s ...
... 21, 2012  Acuo Technologies®, the leader in high-performance ... management and data migration, announces another year of ... achieved sales growth of over 90% from the ... from fiscal year end 2010.  The company signed ...
Cached Medicine Technology:Regeneron Announces February 2012 Investor Conference Presentations 2Acuo Technologies Announces Another Significant Growth Year in Sales to Further the Company's Market Leading Position 2
(Date:7/30/2014)... July 30, 2014 According to the Yeast ... is a comprehensive guide that will help candida sufferers get ... few weeks. This book uncovers to readers the truth about ... addition, inside this book, people will discover natural and safe ... such as itching, burning, and irritation of the vagina or ...
(Date:7/30/2014)... WA (PRWEB) July 30, 2014 According to ... Vkool.com, this is a comprehensive guide that teaches people how ... few weeks. The book uncovers to readers the horrible truth ... in its review that inside this book, people will learn ... such as inflammation, asthma, and nasal infections. , Nasal Polyps ...
(Date:7/30/2014)... According to the Critical Bench Program 2.0 Pdf review recently ... men who want to discover how to increase their ... a few months. Inside this book, learners will discover a ... avoid the aches and pains. , Vkool reveals in its ... the reason why stretching and warming up is so important ...
(Date:7/30/2014)... 30, 2014 Neil Haley, the Total Tutor ... GJ Reynolds to find out about what is branding, how ... best brand. , Reynolds is an original founding member of ... Vi Millionaire, and CEO of Simply G Media. He has ... You!" and holds the distinction of completing the Dale Brown ...
(Date:7/30/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... therapy note templates. Healthcare providers can now create ... all while meeting the HIPPA security requirements.     , ... (EMR) consist of psychological intake forms, treatment plan ... SOAP and DAP note formats are also available. ...
Breaking Medicine News(10 mins):Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:Entrepreneur and Vi Millioniare GJ Reynolds Discusses How to Improve Your Brand on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2
... LIVERMORE, Calif. , Feb. 1 The ... recently featured headline stories about a clinical study that is ... surprised by the attention this study is getting from the ... Officer of Halt Medical, Inc., a medical technology company headquartered ...
... could lead to false positives -- adding stress to ... unnecessary follow-up treatment and dietary restrictions. But the ... risk of mental retardation, disability or death outweigh the ... research published today in the February issue of the ...
... ... Santen Inc., as its 2010 president. , ... San Francisco (Vocus) -- Ophthalmic Women Leaders (OWL) has appointed ... , , ,Prior to her appointment as president, Gleeson previously served as chair of ...
... , ... solution to overcome the obstacle of health insurance. , ... (PRWEB) February 1, 2010 -- EasyToInsureME announces a new solution to ... are very afraid. This past week states like Virginia and Pennsylvania are already making laws ...
... A ... ... A report on pedestrian accident statistics released by Elmhurst Hospital Center shows that the number of ... report is being analyzed by New York personal injury attorneys to help their clients., ...
... , Feb. 10 Event With Celebrity Panel To Discuss ... The increased scrutiny of the fashion industry and its use of ultrathin ... say that the fashion industry is at least partially responsible for "girls, ... the Girl Scouts of the USA . , The nationwide survey, ...
Cached Medicine News:Health News:Benefits outweigh risks associated with newborn screening for disorder 2Health News:Ophthalmic Women Leaders (OWL) Names Pamela Gleeson, CFO Of Santen Inc., as 2010 President 2Health News:Recent Shoppers Face Health Insurance Obstacles 2Health News:Recent Shoppers Face Health Insurance Obstacles 3Health News:No Surprise to David Perecman And Other Personal Injury Attorneys, Vehicles Lead All Causes of Injury at New York Hospital 2Health News:No Surprise to David Perecman And Other Personal Injury Attorneys, Vehicles Lead All Causes of Injury at New York Hospital 3Health News:Nationwide Study Finds That Teenage Girls Have Mixed Feelings About the Fashion Industry 2Health News:Nationwide Study Finds That Teenage Girls Have Mixed Feelings About the Fashion Industry 3Health News:Nationwide Study Finds That Teenage Girls Have Mixed Feelings About the Fashion Industry 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: